Triptorelin Pamoate

A to Z Drug Facts

Triptorelin Pamoate

	Action
	Indications
	Contraindications
	Route/Dosage
	Interactions
	Lab Test Interferences
	Adverse Reactions
	Precautions

(trip-toe-REL-in)

Trelstar Depot

Microgranules for injection, lyophilized

Equivalent to 3.75 mg triptorelin peptide base

Trelstar LA

Microgranules for injection, lyophilized

Equivalent to 11.25 mg triptorelin peptide base

Class: Gonadotropin-releasing hormone

Action Synthetic analog of gonadotropin-releasing hormone (GnRH) that acts as potent inhibitor of gonadotropin secretion.

Indications Palliative treatment of advanced prostate cancer and as an alternative treatment for prostate cancer when orchiectomy or estrogen administration are not indicated or unacceptable to the patient.

Contraindications Hypersensitivity to triptorelin or any component of product; other gonadotropin-releasing hormone agonists; pregnancy.

Route/Dosage

Trelstar Depot Adults IM 3.75 mg in a depot formulation administered as a single monthly injection.

Trestar LA Adults IM 11.25 mg in long-acting formulation administered q 84 days.

Interactions

Hyperprolactinemic drugs: Do not administer concurrently with triptorelin.

Lab Test Interferences Since chronic or continuous administration of triptorelin suppresses pituitary-gonadal axis, diagnostic tests or pituitary-gonadal function performed during triptorelin treatment or after cessation of therapy may be misleading.

Adverse Reactions

CARDIOVASCULAR: Hypertension. CNS: Dizziness; emotional lability; headache; insomnia. GI: Diarrhea; vomiting. GU: Bladder outlet obstruction; hematuria; impotence; urinary retention; UTI. HEMATOLOGIC: Anemia. OTHER: Bone pain; fatigue; hot flashes; leg pain; injection site pain; pain; pruritus; skeletal pain; spinal cord compression.

Precautions

Pregnancy: Category X. Lactation: Undetermined. Children: Safety and efficacy not established. Hypersensitivity: Anaphylactic reactions have been reported. Special risk patients: Spinal cord compression or renal impairment have been reported. Worsening signs and symptoms: Drug initially causes transient increase in testosterone, which may lead to worsening of signs and symptoms of prostate cancer (eg, bone pain) during first few weeks of treatment.